Fibrinolytic Therapy

For a patient experiencing an acute ST-elevation myocardial infarction (STEMI), the use of fibrinolytic therapy is an important clinical intervention. The administration of a fibrinolyic agent such as streptokinase (SK) or tissue plasminogen activator (tPA) results in the lysis of the acute thrombus so that the obstructed coronary artery can be opened and blood flow to the affected tissue can be restored. Adjunctive measures, such as the initiation of heparin infusions are then taken to prevent further clot formation and obstruction reoccurrence. Lysis is achieved by converting inactive plasminogen to plasmin, an enzyme that is responsible for the degradation of fibrin.

Patients with recent onset of chest pain with persistent ST elevation and those with underlying bundle branch blocks are ideal candidates for therapy. To ensure maximum effectiveness the a goal of 30 minutes from the onset of the patient’s pain to the administration of the agent, should be set.

Following the lysis of the thrombus, there are several phenomena that may be observed.


Pain

Reperfusion Dysrhythmias

ST segment

Cardiac Biomarkers

Residual Coronary Stenosis

Nursing responsibilities in fibrinolytic therapies include: